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Each year, approximately 795,000 people experience a new or recurrent stroke. Of all
strokes, 84% are ischemic, 13% are intracerebral hemorrhage (ICH) strokes, and 3% are
subarachnoid hemorrhage strokes. Despite the decreased incidence of ischemic stroke,
there has been no change in the incidence of hemorrhagic stroke in the last decade. ICH is a
devastating disease 37–38% of patients between the ages of 45 and 64 die within 30 days.
In an effort to prevent ischemic and hemorrhagic strokes we and others have been studying
the role of prostaglandins and their receptors. Prostaglandins are bioactive lipids derived
from the metabolism of arachidonic acid.They sustain homeostatic functions and mediate
pathogenic mechanisms, including the inflammatory response. Most prostaglandins are
produced from specific enzymes and act upon cells via distinct G-protein coupled receptors.
The presence of multiple prostaglandin receptors cross-reactivity and coupling to different
signal transduction pathways allow differentiated cells to respond to prostaglandins in a
unique manner. Due to the number of prostaglandin receptors, prostaglandin-dependent
signaling can function either to promote neuronal survival or injury following acute excitotox-
icity, hypoxia, and stress induced by ICH.To better understand the mechanisms of neuronal
survival and neurotoxicity mediated by prostaglandin receptors, it is essential to understand
downstream signaling. Several groups including ours have discovered unique roles for
prostaglandin receptors in rodent models of ischemic stroke, excitotoxicity, and Alzheimer
disease, highlighting the emerging role of prostaglandin receptor signaling in hemorrhagic
stroke with a focus on cyclic-adenosine monophosphate and calcium (Ca2+) signaling. We
review current ICH data and discuss future directions notably on prostaglandin receptors,
which may lead to the development of unique therapeutic targets against hemorrhagic
stroke and brain injuries alike.
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INTRODUCTION
Stroke is a leading cause of long-term disability and accounts for
one of every 18 deaths in the United States (Roger et al., 2012).
More than 795,000 people experience a new or recurrent stroke
in the United States each year and 10–15% experience a hemor-
rhagic stroke (Thom et al., 2006; Roger et al., 2012). Although
the incidence of intracerebral hemorrhage (ICH) is lower than
Abbreviations: 15-deoxy-TIC, 15-deoxy-(16-m-tolyl)-17,18,19,20 tetranoriso-
carbacyclin methyl ester; AKT, serine/threonine-specific protein kinase family;
BP, blood pressure; BW245C, (4S)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-
2,5-dioxo)-4-imidazolidineheptanoic acid; BWA868C, 3-[(2-cyclohexyl-2-
hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-4-imidazolidineheptanoic
acid; CA1 pyramidal neurons, Cornu Ammonis-1 pyramidal neurons; CaMK,
Ca2+/calmodulin-dependent protein kinase; cAMP, cyclic-adenosine monophos-
phate; COX, cyclooxygenase; CRTH2, chemoattractant receptor expressed Th2
lymphocytes; CSF, cerebrospinal fluid; Epac, exchange protein directly activated by
cAMP; Gαi-protein, guanine nucleotide-binding protein (inhibitory); Gαq-protein,
guanine nucleotide-binding protein (stimulatory/inhibitory); Gαs-protein, guanine
nucleotide-binding protein (stimulatory); I-BOP, (Z)-7-[(1S,4R,5R,6R)-5-[(E,3R)-
3-hydroxy-4-(4-iodophenoxy)but-1-enyl]-7-oxabicyclo[2.2.1]heptan-6-yl]hept-5-
enoic acid; ICH, intracerebral hemorrhage; ICP, intracranial pressure;IP3R, inositol
that of ischemic stroke, the mortality and disability rates are
greater. It is thought that many of the deleterious effects of ICH
are due to the release of blood, increased intracranial pressure,
and ischemic damage to the surrounding brain tissue (Gong
et al., 2001). Current measures to reduce mortality and increase
functional recovery include early diagnosis, blood pressure man-
agement, hypothermia, and surgical removal of blood and clots
(Adeoye and Broderick, 2010; Kollmar et al., 2010). Due to the
complexity of ICH, the development of effective interventions has
been challenging.
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In experimental models of ICH, increased neuronal loss has
been correlated with the development of localized collection of
blood outside the blood vessels called hematomas (Fernandes et al.,
2000). Hematomas are made up of red blood cells, in turn con-
sisting of hemoglobin, a complex metalloprotein containing four
heme molecules whose iron atoms temporarily bind oxygen mol-
ecules. When released from red blood cells, heme-iron molecules
contribute to the expansion of ICH-induced brain damage (Mac-
donald and Weir, 1991; Hua et al., 2000). Due to the toxic role
of red blood cells in ICH, we and others have been determining
whether intracranial injection of blood mimics many of the hall-
marks of ICH (Wang et al., 2008). Over the past years, we have
been interested in the regulation of the pro-oxidant heme by the
catalytic heme oxygenase enzymes and the impact of this process
on ischemic stroke (Doré et al., 1999; Li et al., 2009; Zeynalov et al.,
2009) and ICH (Wang et al., 2006; Wang and Doré, 2007a, 2008).
Based on the importance of heme toxicity, we are interested in
determining the role of blood components in hemorrhagic stroke
(Namiranian et al., 2005; Wang and Doré, 2007b).
Inflammation is the immune system’s response to infection
and injury, but if persistent, it can also lead to the loss of cel-
lular and organ function. For example, the inflammatory milieu
following a hemorrhagic stroke is integral to the development of
secondary injury; important components of this have traditionally
included the so-called “pro-inflammatory” prostaglandins (Wang
and Doré, 2007b). Despite previous work on experimental ICH
by others, the role of prostaglandin receptors in ICH remains to
be explored. Prostaglandins are a large family of lipids enzymati-
cally derived from arachidonic acid by the cyclooxygenase enzymes
COX-1 and -2. Prostaglandins function by activating correspond-
ing prostaglandin receptors (DP1–2, EP1–4, FP, IP, and TP). The
diversity of the receptors allows prostaglandins to act on an array
of cells with a wide variety of effects. In this review, we discuss
the regulation of prostaglandin receptors through selective phar-
macologic ligands or genetic deletion with regard to stroke with
special emphasis on ICH.
PATHOPHYSIOLOGY AND CLINICAL FEATURES OF ICH
Intracerebral hemorrhage is a medical emergency that requires
rapid diagnosis and management to minimize neuronal loss and
deterioration after ICH. Vomiting, severe headaches, increased sys-
tolic blood pressure, and coma are common symptoms of ICH
and confirmation the ICH incidence is essentially achieved by
neuroimaging techniques (Sarrafzadeh et al., 2003; Goldstein and
Simel, 2005).
VASOCONSTRICTION AND BLOOD PRESSURE
Reversible cerebral vasoconstriction is characterized by severe
headaches with or without seizures and focal neurological deficits,
and constriction of cerebral arteries following occurs in 7% of
ICH patients, and 22% of SAH patients (Ba et al., 2012). Increase
in cerebral vasoconstriction directly affects blood pressure. Ele-
vated blood pressure (BP) at admission has been found to predict
worse outcomes; early intensive BP management reduces the risk
of hematoma expansion (Anderson et al., 2010). Continuous
intravenous infusion of BP lowering drugs aggressively reduces
systolic BP (Manawadu et al., 2010). Prostaglandin E2 (PGE2),
which is synthesized in the vasculature of the brain (within neuron
and glia cells), acts as a powerful endogenous pyrogenic mediator
of the preoptic area by activating specific receptors (Nakamura
et al., 2009). Due to elevated BP, there is an increased risk of hem-
orrhage in the brain. As blood leaks and collects into a hematoma,
pressure builds on nearby brain tissue, reducing vital blood flow,
and killing brain cells.
INTRACRANIAL PRESSURE AND EDEMA
Blood components such as serum may be connected to the patho-
genesis of secondary brain injury after ICH (Wang et al., 2011).
Inflammatory agents released from hematomas can cause the
breakdown of blood-brain barrier,which is a proposed mechanism
of edema (Wagner et al., 1998). Uncontrolled inflammation con-
tributes to brain edema and prostacyclin PGI2 has been reported to
contribute by augmenting the permeability of capillaries (Masada
et al., 2001; Xi et al., 2001, 2002; Bentzer and Grande, 2004).
Following experimental lipopolysaccharide (LPS)-induced edema,
low-dose infusion of PGI2 caused further increase in intracranial
pressure (Gardenfors et al., 2004). Recently, in a mouse model of
subarachnoid hemorrhage (SAH),cerebral edema was reduced fol-
lowing the inhibition of inducible cyclooxygenase-2 (Ayer et al.,
2011). In addition to inflammatory components, iron-mediated
free radical damage can also contribute to secondary damage after
ICH. For example, iron released from heme after the breakdown of
hemoglobin accumulates in the parenchyma and has been linked
to cerebral edema; thus, removal of the hematoma reduces edema
formation (Wagner et al., 1999; Huang et al., 2002; Qing et al.,
2009; Zhao et al., 2011). Due to the significant impact of inflamma-
tory components like prostaglandins following ICH, we propose
that prostaglandin receptors may be ideal targets to fight against
ICH-induced brain edema.
INFLAMMATION
The major inflammatory cells that are activated and accumu-
late within the brain after ICH are blood-derived leukocytes,
macrophages, and resident microglia. In addition, the infiltration
of short-lived neutrophils following ICH contributes to blood
vessel disruption, blood-brain barrier degradation, axon dam-
age, and the glia responses that evolve after ICH (Moxon-Emre
and Schlichter, 2011). Following ischemic stroke, infiltrating neu-
trophils play a role in exacerbating inflammation by up-regulating
matrix metalloproteinase (MMP; Justicia et al., 2003). For exam-
ple, a correlation between MMP-9 activity and hemorrhagic trans-
formation of the ischemic lesion has been reported (Heo et al.,
1999; Lapchak et al., 2000; Sumii and Lo, 2002; Gautier et al., 2009).
In addition to their effect on inflammation, microglial cells are
increasingly being studied as the cell type responsible for the res-
olution of hematomas formed after ICH (Zhao et al., 2007). Data
suggest that microglia activation occurs very early after the onset of
ICH and persists for weeks (Hickenbottom et al., 1999; Xue and Del
Bigio, 2000). However, uncontrolled microglia activation can also
play a role in secondary damage following ICH (Wasserman et al.,
2008). In addition to being expressed in neurons, prostaglandin
receptors are expressed in microglia, astrocytes, and endothelial
cells (Caggiano and Kraig, 1999; Takemiya et al., 2011). Microglia
predominately express EP1 and EP2 receptors, reactive astrocytes
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express EP1 and DP1 receptors and endothelia cells express all
four EP (EP1–4) receptors (Mohri et al., 2007; Carlson et al., 2009;
Taniguchi et al., 2011a). As well as expressing receptors, microglia
and astrocytes are also a source of calcium-mediated PGE2 in the
brain (Sanzgiri et al., 1999; Zonta et al., 2003; Anrather et al., 2011;
Font-Nieves et al., 2012).
Also, due to the increased permeability of the blood-brain
barrier following ICH, blood components, and plasma proteins
enter the brain, initiating an exacerbated inflammatory response
involving glial activation, release of cytokines, chemokines, and
formation of reactive oxygen species, together resulting in the
breakdown of brain tissue and repair (Peeling et al., 1998; Mayne
et al., 2001a,b). For example, in a rat model of ICH induced by
double autologous intrastriatal blood injection, elevated levels of
interleukin-1β and tumor necrosis factor-α was observed at 3 and
24 h after injection (Mayne et al., 2001b).
Growing knowledge of the pathophysiology of ICH has led to
the exploration of neuroprotective strategies aiming to improve its
outcomes through reduction of secondary pathological processes.
Work by us and others have previously shown that prostaglandins
are important agents released in response to ischemic stroke and
their affect is prostaglandin receptor-dependent. Despite some
recent data by our group showing that when deleted, EP1 recep-
tor may exacerbate brain injury in the early hours after ICH
by regulating microglial phagocytosis, further studies of the role
prostaglandin receptors (EP1–4) on the function of cells such
as microglia and neurotrophils after ICH is still needed. More
information on the general role of various cell types modulating
inflammation after ICH can be found in a previous review from
our group (Wang and Doré, 2007b).
SEIZURES
Seizures related to ICH occur in approximately 11% of patients,
although those related to ischemic stroke appear in approximately
9% of patients (De Reuck, 2007). Post-stroke seizures are generally
classified as early- and late-onset seizures, with most early onset
seizures occurring at onset or within the first 24 h of ICH (Takasugi
et al., 1985). Early onset seizures and increased risk of epilepsy are
associated with hemorrhagic stroke (Burn et al., 1997; Berges et al.,
2000; De Herdt et al., 2011). Using animal models of seizure, data
suggest that hemolysis and deposition of iron rich compounds may
play a significant role (Willmore and Triggs, 1991). It is believed
that in iron-induced experimental epilepsy models, seizure activ-
ity is mediated by free radicals and membrane lipid peroxidation
(Jyoti et al., 2009). The role of pro-inflammatory molecules is also
likely to contribute to ICH-related seizures.
In experimental models of kainic acid-induced seizures, COX-2
and PGE2 levels are increased in neuronal and non-neuronal cells
and blockade of COX-2 and/or PGE2 reduced cell death (Takemiya
et al., 2006).Vascular endothelial cells in the brain produce PGE2 in
response to excitotoxicity (Takemiya et al., 2010). When blocked,
PGE2 receptors EP1, EP3, and EP4 and activation of EP2 receptors
have anticonvulsant and neuroprotective properties in different
rodent seizure models (Oliveira et al., 2008; Fischborn et al., 2010;
Takemiya et al., 2011; Rehni and Singh, 2012). Nevertheless, in a
mouse model of pilocarpine-induced status epilepticus consec-
utive inhibition of EP2 receptors after termination of seizures
with antiepileptic drugs significantly reduced hippocampal neu-
ronal injury (Jiang et al., 2012). Furthermore prostaglandin PGF2α
and its FP receptor have been implicated in kainic acid-induced
seizures (Kim et al., 2008). Consequently, it is likely that the pro-
duction of prostaglandins following ICH may contribute to the
incidence and severity of the seizures.
ROLE OF PROSTAGLANDIN RECEPTORS IN ICH
Prostaglandins are generated from arachidonic acid, a 20-carbon
unsaturated fatty acid, which is released from the bilipid layers of
the plasma membrane by the action of three different phospho-
lipases A2: secreted (sPLA2α), and cytosolic calcium-dependent
(sPLA2α) and calcium independent (iPLA2α) and metabolized to
PGH2 by cyclooxygenase enzymes, COX-1 and COX-2 (Kishimoto
et al., 2010). PGH2 is the common substrate for a series of spe-
cific isomerase and synthase enzymes that produce prostaglandins.
Prostaglandins PGE2, PGI2, PGD2, PGF2α, and TxA2 are gener-
ated by the action of their respective synthases: PGE synthase
(cytosolic; cPGES-1, and membrane-associated; mPGES-1 and
mPGES-2), prostaglandin I synthase (PGIS), prostaglandin D
synthase (hematopoietic-type: H-PGDS, and lipocalin-type: L-
PGDS), prostaglandin F synthase (PGFS), and thromboxane syn-
thase (TxS). It should be noted that mPGES-1 was found to
be significantly increased in the AD brains as compared to age
matched controls (Chaudhry et al., 2008, 2010). Once synthesized,
prostaglandins can be further metabolized or they can act on their
specific G-protein coupled receptors.
PROSTAGLANDIN RECEPTOR EXPRESSION (MESSAGE AND PROTEIN)
Elegant work was done to measure the respective affinity of the
various radioactive-labeled prostaglandin ligands to their respec-
tive receptors by expressing each of the receptors in CHO cells
and performing traditional ligand binding assays (Kiriyama et al.,
1997). Furthermore, specific binding of PGD2, PGE2, and PGF2α
were found in rat and human brain tissue (Watanabe et al., 1985).
In postmortem human brains of normal subjects, [3H]-PGD2 and
[3H]-PGE2 bindings were highest in the hypothalamus, amygdala,
and hippocampus followed by cerebellar nuclei and the thala-
mus. In addition [3H]-PGD2 was found in nucleus accumbens
and cerebral cortex. [3H]-PGF2α binding was most abundant in
the amygdala, cingulate cortex, cerebellar medulla, hippocam-
pus, nucleus accumbens, midbrain, and hypothalamus (Watanabe
et al., 1985). Similar regional distribution of PGE2 binding sites
were detected in the rat brain (Matsumura et al., 1992).
PGE2-EP RECEPTOR EXPRESSION
PGE2-EP2 receptors are expressed throughout the PNS and CNS,
for example, at the mRNA level, the EP1 receptor is mainly
expressed in the thalamus and hypothalamus, and have been stud-
ied in neurons and microglia under different pathologic conditions
(Batshake et al., 1995; Caggiano and Kraig, 1999; Kawano et al.,
2006). EP2 receptor mRNA are expressed mostly in astrocytes
and neurons of the cerebral cortex, striatum, hippocampus, and
CA1 pyramidal neurons (Zhang and Rivest, 1999). The mRNA
expressions of EP3 receptor are most abundant in the olfactory
system, hippocampus, and subcortical telencephalic structures in
the septal region and amygdala of the brain (Sugimoto et al.,
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1994; Ek et al., 2000; Nakamura et al., 2000). EP3 receptor mRNA
are expressed mostly in subcortical-hypothalamic regions of the
brain owing to their role in thermoregulation (Vasilache et al.,
2007). The EP3 receptor has multiple splice variants differing in
their C-terminal tails. In human tissue, nine mRNA and eight
isoforms (EP3I, EP3II, EP3III, EP3IV, EP3V, EP3IV, EP3e, and
EP3f) have been described (Kotani et al., 1995, 1997; Schmid
et al., 1995). EP3 receptor variants are mostly expressed in clus-
ters of multiple isoforms; for example, the human uterus expresses
mRNA for EP3V and EP3VI receptor isoforms, whereas in primary
keratinocytes, EP3I, EP3II, and EP3IV splice variants are expressed
(Kotani et al., 2000). Similar to humans, mice also have EP3 recep-
tor alternative splicing that are well characterized EP3 isoforms
(α, β, and γ) and contain carboxyl tails of 30, 26, and 29 amino
acids. EP4 receptor mRNA are expressed in the forebrain, hypo-
thalamus, lower brainstem, and at lower levels in endothelial cells
(Narumiya et al., 1999; Zhang and Rivest, 1999; Li et al., 2008).
Messenger RNA of the EP1–4 receptors was detected both in the
hippocampus and in the neocortex. All four immunoreactive EP
receptors appeared to be detected in neurons and were also present
in astrocytes, though perhaps at weaker levels (Zhu et al., 2005).
IP, DP, FP, AND TP RECEPTOR EXPRESSION
IP receptor mRNA is expressed in many tissue types including
spleen, thymus, aorta, coronary, pulmonary, and cerebral arter-
ies, kidney, and in neuronal cell bodies (Oida et al., 1995). DP1
receptor mRNA is expressed in the cerebral cortex, hippocampal
pyramidal layers, dentate gyrus, thalamus, choroid plexus, and lep-
tomeninges (Oida et al., 1997). The mRNA expression of the FP
receptor has been previously demonstrated in mouse brains and in
brain synaptosomes of newborn pigs and in human eye tissue (Li
et al., 1993; Kitanaka et al., 1994; Liang et al., 2008). FP receptor
mRNA is highly expressed in rodent whole brain (www.brain-
map.org; Kitanaka et al., 1994). The FP receptor is also expressed
in neuronal and astrocyte cultures (Kitanaka et al., 1991, 1993;
Gotoh et al., 1994). In the brain, astrocytes, oligodendrocytes, and
white matter of the striatum express TP receptor mRNA (Borg
et al., 1994; Kitanaka et al., 1995, 1996; Honma et al., 2006). Like
the expression patterns of prostaglandin receptors, when activated,
the signaling cascades that follow are also varied.
Figure 2 illustrates the overview of prostaglandin receptor-
mediated signaling. Depending on a given prostaglandin recep-
tor, we and others have found that global deletion of specific
prostaglandin receptors can greatly influence stroke outcomes
(Ahmad et al., 2005, 2006a, 2008, 2010a; Saleem et al., 2007a,
2009a,b,c). However, the mechanisms that mediate these outcomes
following ICH have not been fully elucidated. The prostaglandin
receptors can be grouped according to the downstream signaling
pathways they activate.
PROSTAGLANDIN RECEPTORS AND SIGNALING
Prostaglandins exert cellular affects through their specific recep-
tors: PGE2 receptors EP1, EP2, EP3, and EP4; PGD2 receptors
DP1 and DP2; PGF2α receptor FP; PGI2 receptor IP; and TxA2
receptor TP (Narumiya et al., 1982, 1991, 1999; Ogorochi et al.,
1984; Narumiya and Toda, 1985; Ito et al., 1989; Namba et al.,
1992, 1994; Honda et al., 1993; Irie et al., 1993; Watabe et al., 1993;
Hirata et al., 1994a, 1996; Katsuyama et al., 1994, 1995; Hasegawa
et al., 1996; Ishikawa et al., 1996; Kiriyama et al., 1997; Kobayashi
and Narumiya, 2002; Woodward et al., 2011). Alternative splicing
of the C-terminal has generated additional isoforms of human TP
(TPα, TPβ), FP (and some relatively rare splice variants, not recep-
tor subtypes), and eight EP3 receptor isoforms (Narumiya and
Fitzgerald, 2001). Both human and mouse prostaglandin recep-
tors signal via either Gαs (EP2, EP4, IP, and DP1 receptors) to
increase intracellular levels of cyclic-adenosine monophosphate
(cAMP), or Gαq (EP1, EP3, and FP) to increase intracellular lev-
els of calcium or Gαs-proteins (EP3, DP2, and TP receptors) to
increase or decrease intracellular levels of cAMP and calcium.
Table 2 depicts these prostaglandin receptors and their signaling
and binding properties.
In addition to cAMP-PKA dependent second messenger signal-
ing, which activates G-protein, G-protein activation also occurs
via a PKA-independent mechanism. An example of protein acti-
vated by cAMP but PKA-independent include the exchange pro-
tein directly activated by cAMP (Epac1 and 2). Epac1 and 2
function as guanine nucleotide exchange factors for the small G-
protein Rap. Epac proteins are expressed throughout the body,
with Epac1 specifically abundant in blood vessels, kidney, adi-
pose tissue, CNS, ovary, and uterus, whereas Epac2 is mostly
expressed in the CNS, adrenal gland, and pancreas (de Rooij et al.,
1998; Kawasaki et al., 1998). Due to the abundance of GPCRs
that mediate cAMP signaling, Epac proteins have many biological
functions. For example, Epac regulates electrically evoked Ca2+
transients in response to β-adrenergic receptors, Epac2 activation
induces exocytosis in human β cells, increasing the number of
exocytic sites on the plasma membrane via its effects on Ca2+
signaling, and effects neuronal function following activation by
potentiating the postsynaptic excitation currents (Kang et al., 2003;
Kaneko and Takahashi, 2004; Wang et al., 2005; Cheung et al.,
2006; Gekel and Neher, 2008). Furthermore, together with PKA,
Epac also contributes to the regulation of neuronal differentia-
tion, neurite outgrowth, and axon generation, implicating an Epac
role in the development and maintenance of the nervous system
(Christensen et al., 2003; Kiermayer et al., 2005; Shi et al., 2006;
Murray and Shewan, 2008). In addition and perhaps relevant to
the ICH-pathology, Epac proteins have been implicated in vascular
function.
In vivo administration of a Epac agonist (007) inhibited vas-
cular endothelial growth factor-induced dye leakage from mouse
dermal blood vessels (Fukuhara et al., 2005). Also, 007 induced
secretion of von Willebrand factor-containing Weibel–Palade bod-
ies, which may further contribute to the regulation of vasculature
homeostasis by Epac1 (Rondaij et al., 2004). Epac proteins have
also been implicated in inflammation, where cAMP signaling
directly controls inflammation by regulating leukocyte-mediated
immune responses (Lorenowicz et al., 2007). Epac proteins are
expressed in leukocytes and following the activation of Epac1 reg-
ulate the monocytes adhesion and chemotaxis (Lorenowicz et al.,
2006). Epac1 also induces pathogen-mediated production of pro-
inflammatory cytokines and chemokines (Gerlo et al., 2010). Due
to recent reports on the role of Epacs in the brain and neurons,
we hypothesis that Epacs may function to minimize neuronal
death involved in ICH. Such Epac-mediated neuroprotection may
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occur by potentiating PKA-independent activation of the small
G-protein Rap by cAMP. Mechanisms of Epac-dependent neu-
roprotection remain to be studied in correlation to prostaglandin
receptor activation. Protein homology between human and mouse
prostaglandin receptors are at best 88% (i.e., human FP receptor
vs. mouse FP receptor) with little homology between receptor sub-
types. A phylogenetic tree and table of the amino acid homology
(% identity) between human and mouse prostaglandin receptors is
illustrated in Table 1 and Figure 1, respectively. Due to the mech-
anistic nature of prostaglandin receptors, evolutionary relation-
ships among human and mouse prostaglandin receptors can be
broadly grouped into two signaling pathways: essentially leading to
cAMP or calcium signaling cascade. Table 2 and Figure 2 illustrate
signal transduction mechanisms activated when prostaglandin
receptor specific agonist bind. Prostaglandin receptors have been
grouped into specific G-protein-dependent cAMP and/or Ca2+
signaling. Prostaglandin receptors are expressed throughout the
peripheral and central nervous system and therefore play an
important role in the physiologic response following injury.
PROSTAGLANDIN RECEPTORS (IP, DP1, EP2, EP4)
ACTIVATING cAMP PATHWAY
PGI2-IP RECEPTOR
Prostacyclin is a primary prostaglandin produced by endothelial
cells and plays an important role in vascular homeostasis (Vane
and Botting, 1995). Through the activation of its IP receptor, PGI2
induces vasodilation, inhibits platelet aggregation at high concen-
trations, and proliferates smooth muscle cells via Gαs-proteins,
and increased cAMP levels (Moncada et al., 1977a,b; Falcetti et al.,
2010). Due to their tendency for post-translational modifications,
the IP receptors are capable of coupling to other signal trans-
duction pathways via Gαq-protein dependent phosphoinositide
turnover and Gαi-protein dependent inhibition of cAMP (Kat-
suyama et al., 1994; Hebert et al., 1998; Miggin et al., 2003). IP
receptor-mediated vasodilation may also be modulated by the
co-activation of EP3 receptors that couple to Gαi-proteins and
therefore further research on role of PGI2-IP receptor following
stroke is required (Orie and Clapp, 2011).
The role of PGI2 in response to neuronal injury or toxicity was
measured using rat cortical neuron cultures subjected to hypoxia
and glutamate toxicity (Cazevieille et al., 1993, 1994). Following
transient ischemia in mice, PGIS and PGI2 levels are increased
in neurons, macrophages, and microglial cells of the brain (Fang
et al., 2006). Increased levels of PGIS and PGI2 provided neuropro-
tection against ischemia indicated by a reduction in infarct volume
following adenovirus mediated overexpression of PGIS 72 h after
ischemia (Fang et al., 2006). The role of IP receptors in stroke was
not determined until recently.
We have also demonstrated the neuroprotective properties
of the IP receptor in mouse models of transient middle cere-
bral artery occlusion (tMCAO) and permanent distal MCAO
(pMCAO; Saleem et al., 2010). IP receptor knockout mice showed
increased infarct volumes and neurological deficit scores com-
pared with wildtype mice, and pretreatment with a selective IP
receptor agonist (beraprost) reduced infarct volumes and deficit
scores, confirming the neuroprotective role of IP receptor activa-
tion (Saleem et al., 2010). In addition, our group also found that
Table 1 | Amino acid homology (% identity) between human (h) and
mouse (m) prostaglandin receptors.
Receptor hEP1 hEP2 hEP3 hEP4 hFP hIP hTP hDP1 hDP2
mEP1 85 28 30 23 34 23 29 22 12
mEP2 25 85 25 32 18 38 23 41 11
mEP3 33 24 79 25 29 27 30 23 15
mEP4 26 23 23 88 20 34 22 29 13
mFP 34 20 30 19 88 21 34 20 14
mIP 23 40 25 25 20 79 25 37 15
mTP 34 23 28 24 34 27 74 24 14
mDP1 24 41 22 29 18 36 23 71 14
mDP2 (CRTH2) 24 41 22 29 18 36 23 12 79
EP1 (Accession no. h: NP_000946.2 m: NP_038669.1), EP2 (Accession no.
h: NP_000947.2m: NP_032990.1), EP3 (Accession no. h: NP_942009.1 m:
NP_032991.1), EP4 (Accession no. h: NP_000949.1 m: NP_000949.1), FP (Acces-
sion no. h: NP_000950 m: NP_032992.1), IP (Accession no. h: NP_000951 m:
BAA05144), TP (Accession no. h: NP_963998 m: NP_033351.1), DP1 (Acces-
sion no. h: NP_000944.1 m: NP_032988.3), and DP2 (CRTH2; Accession no. h:
AAR92484.1 m: BAC81437.1). Pairwise sequence alignment determined using
CLUSTALW 2.1 Multiple sequence alignment software. Bold shows amino acid
homology (%) between same receptor types expressed in human and mice.
FIGURE 1 | Phylogenetic tree of human (h) and mouse (m) EP1, EP2,
EP3, EP4, FP, IP,TP, DP1, and DP2 (CRTH2) receptors. Tree was
constructed using pairwise sequence alignment determined using
CLUSTALW 2.1 Multiple sequence alignment software and presented as
NJplot. Evolutionally conserved prostaglandin receptors can be grouped
into signaling pathways: cAMP stimulating and calcium signaling.
when deleted, IP receptors aggravated hippocampal neuronal loss
after bilateral common carotid artery occlusion in mice (Wei et al.,
2008). The neuroprotective role of these CNS-specific IP receptor
ligands was also demonstrated in monkeys subjected to MCAO
(Cui et al., 2006).
Some reports suggest the existence of tissue specific subtypes
of IP receptors. It is noteworthy that the activation of IP recep-
tor (IP2) in the CNS prevented oxygen-induced neuronal death
and protected CA1 pyramidal neurons against ischemia in gerbils
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Table 2 | Structural, signal transduction, and agonist binding properties of mouse prostaglandin receptors.
Receptor Amino acids: human vs. mouse Signaling Agonist binding K i (nM)
EP1 402 (human), 405 (mouse) Gαq: ↑ [Ca2+]i PGE2>PGE1>PGF2α 20.00, 36.00, 1300.00
EP2 358 (human), 362 (mouse) Gαs: ↑ cAMP PGE1>PGE2 10.00, 12.00
EP3 365–425 (human), 361–365 (mouse) Gαq: ↑ [Ca2+]i
Gαi: ↓ cAMP
PGE2>PGE1 0.68, 0.85
EP4 488 (human), 513 (mouse) Gαs: ↑ cAMP PGE2>PGE1 1.90, 2.10
FP 359 (human), 366 (mouse) Gαq: ↑ [Ca2+]i PGF2α>PGD2 3.40, 470
IP 386 (human), 417 (mouse) Gαs: ↑ cAMP PGE1 33.00
TP 343 (human), 341 (mouse) Gαq: ↑ [Ca2+]i *[I-BOP] 0.68
DP1 359 (human), 357 (mouse) Gαs: ↑ cAMP PGD2 21.00
DP2 (CRTH2) 395 (human), 382 (mouse) Gαq: ↑ [Ca2+]i
Gαi: ↓ cAMP
PGD2 45.00
*[I-BOP]: TP receptor agonist; used as a replacement for TxA2 due to very short half-life of TxA2.
FIGURE 2 | Signal transduction mechanisms of activated prostaglandin receptors. Prostaglandin receptors have been grouped into specific
G-protein-dependent cAMP and/or Ca2+ signaling.
(Takechi et al., 1996; Satoh et al., 1999; Watanabe et al., 1999).
In rats subjected to MCAO, the effects of an IP receptor ligand
(15-deoxy-TIC) designed to bind the IP2 receptor was found to be
significantly neuroprotective when compared with the peripheral
type IP receptor ligand, iloprost methylester, administered 24 h
after ischemia (Takamatsu et al., 2002).
From evidence supporting the neuroprotective role of IP recep-
tors, we hypothesize that activation of IP receptor could also
serve to protect from ICH. The effects of increased IP receptor-
dependent activation of cAMP signaling following ICH remain to
be fully elucidated. Inversely, because of the vasodilatory proper-
ties of PGI2, it is possible that the activation of IP receptors would
also potentially exacerbate the hemorrhagic transformation and
hemorrhagic damage.
PGD2-DP1 RECEPTOR
PGD2 has both peripheral and central physiologic effects (Whit-
tle et al., 1983; Narumiya and Toda, 1985; Casteleijn et al., 1988;
Sturzebecher et al., 1989; Darius et al., 1994; Matsugi et al., 1995;
Matsuoka et al., 2000; Angeli et al., 2004). Activated DP1 receptor
leads to the activation of the cAMP/PKA pathway and is one of the
main cellular mechanism through which DP1 receptors exert their
neuroprotective effects (Liang et al., 2005). Activation of the DP1
receptor stimulates adenylyl cyclase, leading to increased levels of
cAMP, and decreased platelet aggregation (Hata and Breyer, 2004).
PGD2 levels are significantly increased under pathologic condi-
tions; however, the effects of PGD2 remain dependent on the cell
type (Hata and Breyer, 2004; Hatoum et al., 2005). For exam-
ple, PGD2 inhibited TNF-α-induced migration of Langerhans
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cells, which are involved in cutaneous inflammatory responses by
decreasing the infiltration of T helper cells (Angeli et al., 2004). The
anti-inflammatory properties of PGD2 are primarily associated
with DP1 receptors. For example, DP1 receptor activation resulted
in decreased allergic and asthma response (Matsuoka et al., 2000;
Hammad et al., 2003; Angeli et al., 2004).
In the brain, until recently DP1 receptor related studies were
limited to investigations of sleep induction, modulation of body
temperature,olfactory function,hormone release,nociception,eye
movement, and neuromodulation (Eguchi et al., 1999; Urade and
Hayaishi, 1999; Mizoguchi et al., 2001; Hayaishi, 2002; Obal and
Krueger, 2003; Angeli et al., 2004; Hata and Breyer, 2004; Gelir
et al., 2005; Koch et al., 2005). In addition to expression and func-
tion in the brain, the neuroprotective effects of the DP1 receptor
was revealed following activation by PGD2 protected hippocampal
cultures derived from E18 rat embryos against glutamate toxicity
(Liang et al., 2005). In a mouse model of cerebral ischemia, we
and others have shown that PGD2 mediates neuroprotection via
the DP1 receptors (Liang et al., 2005; Saleem et al., 2007c). We
have also shown that NMDA-induced excitotoxicity and cerebral
ischemic brain damage were significantly attenuated by the DP1
receptor-selective agonist BW245C (Ahmad et al., 2010a).
Although the potential neuroprotective effect of DP1 receptors
has been reported, the signaling cascade leading to this neuro-
protective effect remains unclear. Based on the reports from us
and others, it is evident that activation of DP1 receptors leads to
increased levels of cAMP/PKA. However, more experiments are
required to fully elucidate the role of DP1 receptors in ICH. Based
on the role of DP1 receptors in activating the cAMP/PKA pathway,
we expect that these receptors could be novel endogenous targets
in attenuating ICH. However, the vasodilatory effect of PGD2 and
DP1 could also pose a higher risk of hemorrhage. Nevertheless, use
of pharmacologic and genetic approaches targeting DP1 receptors
could provide better insight and might help in protecting the brain
from devastating hemorrhagic conditions.
PGE2-EP2 RECEPTOR
Among various effects of PGE2 many of them have been attrib-
uted to its known capacity to stimulate cAMP via EP2 receptors
and selective agonist also increase cAMP levels in a concentration-
dependent manner with the same potency as PGE2 (Narumiya
et al., 1999). EP2 receptor-selective agonists increase the cAMP lev-
els in a concentration-dependent manner with the same potency
as PGE2 (Choi et al., 2001). PGE2-stimulated cAMP formation
has been shown to be blocked not only by an EP1/EP2 receptor
antagonist, AH6809, but also by an inhibitor of adenylyl cyclase,
SQ22536 (Fiebich et al., 2001).
In the brain, activation of EP2 receptors by PGE2 is involved in
long-term synaptic plasticity and cognitive function, where mice
deficient in EP2 receptors showed impaired hippocampal synap-
togenesis (Sang et al., 2005; Yang et al., 2009). Therefore it is no
surprise that brain injuries can affect the expression and function
of EP2 receptors. For example, EP2 receptor expression increased
in CA1 pyramidal neurons following cerebral ischemia in rats
(Choi et al., 2006). However, does this increase in expression of
EP2 receptors following brain injury result from its neuroprotec-
tive properties when activated? In support of this question, our
group and others have shown EP2 receptor-mediated neuropro-
tection when subjected to glutamate receptor-mediated toxicity
and MCAO and that EP2−/−mice has increased damage (Liu et al.,
2005; Ahmad et al., 2006b). In a mouse model of focal cerebral
ischemia, we have shown that butaprost, an EP2 receptor-selective
agonist, provided dose-dependent neuroprotection, whereas dele-
tion of EP2 receptors aggravated ischemic brain damage (Ahmad
et al., 2010b). Neuroprotection mediated by EP2 receptor activa-
tion occurs by a PKA-dependent mechanism, as demonstrated,
against oxidative stress and excitotoxicity (Echeverria et al., 2005).
Additional studies support the mechanism by which
PGE2 affords neuroprotection through EP2 receptor-associated
increases in cAMP, followed by a PKA-dependent pathway (Araki
et al., 2000; McCullough et al., 2004; Jiang et al., 2010). In an
attempt to discover neuroprotective agents, EP2 receptor agonist
conferred neuroprotection in an NMDA receptor-induced excito-
toxicity model, strongly reinforcing the notion that EP2 receptor
activation by endogenous PGE2 in a cell-injury setting is neuro-
protective (Jiang et al., 2010). These findings and others suggest the
cAMP/PKA pathway is the site of neuroprotection following EP2
receptor activation (Araki et al., 2000; McCullough et al., 2004; Liu
et al., 2005). In addition to EP2 receptor-mediated PKA-dependent
neuroprotection, cAMP activation independent of PKA may also
afford neuroprotection. However, recent studies have reported that
PGE2 activation of the EP2 receptor had anti-proliferative effects
in human gingival fibroblasts and this seems to be mediated by the
EP2-cAMP-Epac pathway (Weinberg et al., 2009). Research on cor-
tical neurons showed increased apoptosis through the expression
of the Bcl-2 interacting membrane protein Bim and may therefore
warrant further research on how Epac regulation may be used as
a strategy for the treatment of ICH (Suzuki et al., 2010).
In contrast to previous studies demonstrating the neuropro-
tective effects of EP2 receptor activation, a recent study showed
that when blocked using a selective small molecule EP2 recep-
tor antagonist also significantly reduced neuronal injury in the
hippocampus when administered in mice beginning 1 h after ter-
mination of pilocarpine-induced status epilepticus (Jiang et al.,
2012). This study provides unique insight into the effects of EP2
receptor blockade and may also prove to be a therapeutic strategy
for inflammation-related brain injuries such as ICH. Identifica-
tion of the specific PGE2 receptor subtypes involved in acute brain
injury following ICH will provide the building blocks for future
studies aimed at generating new tools for possible therapeutic
interventions. Similarly to EP2 receptors, EP4 receptors have been
found to activate the cAMP/PKA pathway; however, EP2 and EP4
receptors have significant differences.
PGE2-EP4 RECEPTOR
Like the EP2 receptor, most of the effects PGE2 mediated activa-
tion of EP4 receptor is due to cAMP signaling; however, there is a
subtle difference between their abilities to stimulate cAMP. Using
COS cells expressing both EP2 and EP4 receptors, PGE2 stimula-
tion produced ∼11- and ∼8-fold increase in cAMP, respectively
(Honda et al., 1993; Regan et al., 1994). EP4 receptor-mediated
weaker coupling to Gαs-proteins suggests cAMP plays a less impor-
tant role in EP4 receptor signaling compared to EP2 receptors
(Fujino et al., 2002, 2005). Regardless of the differences in the
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formation of intracellular cAMP, EP4 receptor had a greater affin-
ity for PGE2 than the EP2 receptor (Fujino et al., 2003). Com-
pared to EP2, EP4 also has a longer C-terminus, which has been
implicated in agonist-induced desensitization and internalization
(Nishigaki et al., 1996; Bastepe and Ashby, 1999; Desai et al., 2000).
Despite the low levels of intracellular cAMP, when activated fol-
lowing injury, the EP4 receptor has proven to have neuroprotective
properties.
It is well documented that EP4 receptor activation has anti-
inflammatory effects (Narumiya, 2009; Shi et al., 2010; Tang et al.,
2012). Also, in the same study, conditional inactivation of EP4
receptor in neurons and endothelial cells increased infarct size in
mice subjected to MCAO. In addition to its neuroprotective effects,
EP4 receptor activation blocked LPS-induced pro-inflammatory
gene expression in the brain tissue of mice. Additionally, an in vivo
study by the same group, demonstrated that conditional deletion
of EP4 receptor in macrophages and microglia increased lipid per-
oxidation and pro-inflammatory gene expression in the brain (Shi
et al., 2010). We have shown that β-amyloid-induced (Aβ42) tox-
icity is minimized by EP4 receptor activation (Echeverria et al.,
2005). Similarly, following acute striatal excitotoxicity, activation
of EP4 receptor protected the brain (Ahmad et al., 2005).
In addition to their role in neuroprotection, endothelial cells
expressing EP4 receptor are involved in vasodilation due to the
direct activation of endothelial NOS, thus their role in the relax-
ation of smooth muscles (Dumont et al., 1999). Because EP4 recep-
tor signaling is more complex (involving not only Gαs-protein
mediated increase in cAMP but also coupling to pertussis toxin-
sensitive Gαi-proteins and β-arrestin mediated effects), the role
of EP4 receptors in ICH may be more dynamic than in ischemic
stroke (Penn et al., 2001; Fujino and Regan, 2006).
Due to the role of EP4 receptors in vasodilation, we hypothe-
size that activation of EP4 receptors may play an important role
in the control of cerebral blood flow, and thus may represent a
novel target for the prevention or treatment of cerebral ischemia.
In ICH, the endothelium and cerebral vasculature are compro-
mised by potential brain injury with the expansion of blood away
from the region of hematoma. To date, the exploration of EP4
receptors as a target to protect or rescue neurons from blood com-
ponents after ICH remains to be studied. As mentioned, the effects
of PGE2 are vast and beyond the scope of this review; however, the
varied effects of the PGE2 may be attributed to the receptors onto
which it binds and activates. For example, PGE2 when bound to its
receptors cannot only stimulate cAMP signaling but also calcium
signaling by binding to EP1 and FP receptors.
PROSTAGLANDIN RECEPTORS (EP1 AND FP) ACTIVATING
CALCIUM PATHWAY
PGE2-EP1 RECEPTOR
When activated, EP1 receptors couple to Gαq-proteins, resulting in
increased phosphatidyl inositol hydrolysis and elevation of intra-
cellular Ca2+. EP1 receptor activation by PGE2 leads to increased
Ca2+ signaling and subsequent neurotoxicity (Kandasamy and
Hunt, 1990; Kawano et al., 2006). EP1 receptor-mediated neu-
ronal toxicity was found to be normalized to basal levels follow-
ing either blockade or deletion of EP1 receptors, and improved
function of the Na+/Ca2+ exchanger (Kawano et al., 2006). Glial-
derived neurotrophic factor (GDNF) therapy has been shown to
be beneficial in treating Parkinson’s disease when EP1 receptor
is blocked or ablated, resulting in a 60% enhancement in GDNF,
which suggests that selective inhibition of EP1 receptor signaling
might be a means to augment GDNF secretion in diseased regions
of the brain (Li et al., 2012).
Due to decreased calcium signaling, pharmacological blockade
of EP1 receptor could make good therapeutic targets against brain
injury (Gendron et al., 2005). Therefore, using EP1−/− mice and
selective EP1 receptor antagonist, we and others have found that
EP1 receptors contribute to excitotoxicity following focal cerebral
ischemia (Ahmad et al., 2006a, 2008; Saleem et al., 2007b; Abe et al.,
2009). Using a neonate model of hypoxic-ischemia encephalopa-
thy, EP1 receptor blockade with a selective antagonist, SC-51089,
and co-activation of EP2–4 receptors, cerebral injury was reduced
24 h after injury (Taniguchi et al., 2011b). The role of Ca2+ sig-
naling in neuronal activity and death following ICH is unknown;
however, current data suggests that increased Ca2+ signaling con-
tributes to increased cerebral vasospasm commonly seen in SAH
(Kikkawa et al., 2010; Koide et al., 2011). Neuroprotection fol-
lowing the blockade of EP1 receptor has been found to involve
the PTEN/AKT survival pathway following ischemic stroke (Zhou
et al., 2008; Abe et al., 2009). Relating the blockade of EP1 receptor
to neuroprotection in vivo may be complicated by the role of var-
ious cells types; for example, neuroprotection via the blockade of
EP1 receptor was reduced by the presence of microglia in NMDA
stimulated neuron-glial cultures (Carlson et al., 2009). The role
of EP1 receptor in ICH is unknown. However, one study showed
increased expression of EP1 receptors following hemorrhage in
splenic macrophages from male mice (Stapleton et al., 2004).
Data accumulating thus far from ischemic brain injuries and
recent data from our group on ICH suggests that activation of EP1
receptor might lead to different outcomes in different ICH models.
Models of ICH at different time points, using both EP1 receptor
knockout and pharmacological approaches to elucidate the role
of EP1 receptor would increase our in vivo knowledge of EP1
receptors in ICH. Therefore,we recommend further detailed inves-
tigations into the potentialities of EP1 receptor as a therapeutic
target.
PGF2α-FP RECEPTOR
The amino acid sequence of FP receptor has a high sequence
homology with that of the PGE2-EP1 receptor, and shares the same
phylogenetic branch with EP1 receptor (Toh et al., 1995). Despite
the abundance of arachidonic acid in the brain, the function of
its metabolite, PGF2α, is poorly understood. However, PGF2α is
known to play a significant role in the initiation of parturition,
renal function, control of cerebral blood flow, and intraocu-
lar pressure principally by an increase in uveoscleral outflow of
aqueous humor, autoregulation in newborn piglets, contraction
of arteries, and myocardial dysfunction (Chemtob et al., 1990;
Sugimoto et al., 1997; Takayama et al., 2005; Jovanovic et al., 2006;
Hao and Breyer, 2007). Pathological conditions in humans influ-
ence PGF2α levels in cerebrospinal fluid, where elevated levels
of PGF2α were measured following epilepsy, meningtitis, brain
injury, and stroke (Wolfe and Mamer, 1975; Kostic et al., 1984).
Interestingly, elevated levels of PGF2α in the CSF of patients
following acute cerebral ischemia did not correlate with the degree
of neurological deficit (Kostic et al., 1984).
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Activation of FP receptor initiates several events, including
stimulation of the phospholipase C/IP3R/Ca2+ signaling path-
way (Heaslip and Sickels, 1989; Abramovitz et al., 1994; Knock
et al., 2005). FP receptor activation causes the release of Inos-
itol 1,4,5-triphosphate and diacylglycerol in turn activating the
calcium-calmodulin-CaMK-II pathway, which may be associated
with FP receptor-mediated excitotoxicity following transient focal
brain ischemia (Narumiya et al., 1999; Saleem et al., 2009a). Using
FP−/− mice we have shown that FP receptor is involved in the
enhancement of cerebral ischemia and excitotoxic brain injury and
may mitigate the effects of ischemic stroke brain injury (Saleem
et al., 2009a). Recently, we have also demonstrated that FP recep-
tor blockade and knockout protects against ischemic stroke in
mice and oxygen-glucose deprivation-induced cell death in slice
cultures (Kim et al., 2012).
Although FP receptor has been implicated in ischemic stroke,
the roles of PGF2α and FP receptor have not been studied in the
pathogenesis of ICH. Because FP receptor regulates [Ca2+]i levels,
we propose that the activation subsequent to injury contributes to
excitotoxicity and hemorrhagic brain damage. Therefore, blockade
of FP receptor would be beneficial for the treatment of ischemic
stroke.
PROSTAGLANDIN RECEPTORS (EP3, TP, DP2) ACTIVATING
BOTH cAMP AND/OR CALCIUM PATHWAY
PGE2-EP3 RECEPTOR
Because of its coupling to several G-proteins the EP3 receptor
has various biological properties. EP3 is important in a num-
ber of physiological functions including vasoconstriction of the
pulmonary arteries, growth inhibition of keratinocytes, and inhi-
bition of aromatase activity in breast fibroblasts (Qian et al., 1994;
Konger et al., 1998, 2005; Richards and Brueggemeier, 2003). The
EP3 receptor has multiple splice variants that differ in both their
C-terminal tails and signaling pathways (Kotani et al., 1995). The
activation of the human EP3 subtypes EP3I, EP3II, EP3III, EP3IV,
EP3e, and EP3f isoforms have been shown to inhibit cAMP pro-
duction, whereas stimulation of EP3I, EP3II, and EP3III increase
IP3/[Ca2+]i (Kotani et al., 1995; Schmid et al., 1995). The EP3
receptor isoforms expressed in mice (α, β, and γ) contain carboxyl
tails of 30, 26, and 29 amino acids that modulate signal transduc-
tion (Irie et al., 1994). In this context, EP3α and EP3β receptors
couple to Gαi-proteins and inhibit cAMP, whereas the EP3γ cou-
ples to Gαs-proteins in addition to Gαi-proteins and evokes cAMP
production (Sugimoto et al., 1993). In neurological diseases such
as stroke, the function of EP3 receptor so far is not firmly defined;
this may be in part due to the variants of the EP3 receptor subtypes.
When activated with selective EP3 receptor agonist ONO-AE-
248, our group recorded a dose-dependent increase in infarct
volume after MCAO in mice (Ahmad et al., 2007). Recently, the
proposed mechanism of EP3 receptor-mediated neuronal death in
stroke has been implicated by the glutamate-dependent increase in
mPGES-1 activity, which in turn increases EP3 receptor activation
and activation of Rho and/or Gαi proteins signaling (Ikeda-Matsuo
et al., 2010). In contrast to EP3 activation, we have shown that
the deletion of EP3 receptor results in decreased infarct volume
48 h after ischemia (Saleem et al., 2009b). Another group showed
that deletion of the EP3 receptor did not alter infarct volume or
behavior 24 h after ischemia (Li et al., 2008). The discrepancy in
results could be due to differences in time points post-MCAO used
to measure infarct volume and the age of the mice used in both
studies. Also, recently it has been shown that when EP3 receptors
are deleted, damage is done to the blood-brain barrier, activation
of microglia and infiltration of neutrophils into the ischemic cor-
tex are reduced, and the underlying neuroprotection mediated by
EP3 receptor deletion may be due to decreased inflammation and
apoptotic signaling (Ikeda-Matsuo et al., 2011).
No current study has correlated the activation of EP3 recep-
tors in ICH. Three isoforms of the EP3 receptor are expressed
in mice; consequently, the EP3 receptor role in ICH may prove
to be different than its role in ischemic stroke because different
cell types may not only express different levels of EP3 receptors,
but their functions may be different after ICH. Furthermore, due
to the differences between isoforms, it is possible that the dose
and time lapse in administration of EP3 receptor drug treatments
post-stroke could regulate the final outcomes. Therefore, use of
conditional EP3 receptor transgenic animals or a therapeutically
selective agonist/antagonist for these EP3 receptor isoforms could
be beneficial in discerning the role that each of these isoforms plays
following ICH.
TXA2-TP RECEPTOR
TxA2-TP receptor activity is coupled with Gαs-, Gαq-, Gαi-, and
Gα12/13/15/16-proteins (Shenker et al., 1991; Laugwitz et al., 1996;
Muck et al., 1998). These G-proteins in turn regulate several
effectors including phospholipase C, adenylyl cyclase, cAMP, gua-
nine nucleotide exchange factor of the small G-protein Rho, and
intracellular calcium (Kozasa et al., 1998). In humans there are
two isoforms of TP receptors, TPα (placental/platelet) and TPβ
(endothelial), which account for some of the differences in intra-
cellular signaling after activation of TP receptors. These isoforms
differ in length and sequence at the C-terminal distal to the last
amino acid (Arg328) and are expressed in most tissues including
platelets, placenta, vascular smooth muscle, brain, small intestine,
and thymus (Colman, 1991; Hirata et al., 1991; Namba et al., 1992;
Ushikubi et al., 1993; Raychowdhury et al., 1994; Miggin and Kin-
sella, 1998). Despite the relatively limited physiological role of TPβ
receptors, their activation results in pertussis toxin-sensitive inhi-
bition of cAMP (Namba et al., 1992; Hirata et al., 1996). In mice,
no TP receptor isoforms exist; therefore, TP receptors in mice are
considered to be similar to human TPα (74% identical, see Table 2
and Figure 1) and when activated, mediate the increase in cAMP
following I-BOP (a TP receptor agonist) treatment.
Due to the isoforms, TP receptor signaling in humans varies
with tissue type. For example, in platelets, TP receptor coupling
to Gαq-proteins results in increased [Ca2+]i (Hirata et al., 1994b).
In addition, platelet activation may also occur due to theGα12/13-
protein pathways (Offermanns et al., 1996). In the CNS, hip-
pocampal TP receptor plays a functional role in both neuronal
excitability and synaptic transmission (Schwartz-Bloom et al.,
1996). Activation of presynaptic TP receptor results in increased
glutamate release, and postsynaptic activation of TP receptor
results in the inhibition of synaptic transmission, suggesting that
TP receptor plays different roles based on localization (Hsu and
Kan, 1996). Moreover, activation of TP receptor dose-dependently
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suppressed whole-cell Ca2+ currents in rat CA1 neurons (Hsu
et al., 1996).
TP receptors play an important role in the development of cere-
bral ischemia and mediate vascular proliferation and contraction
(De Clerck and Janssen, 1990). Following SAH, mRNA and pro-
tein levels of TP receptors were elevated in cerebral arteries and
smooth muscle cells, respectively (Ansar et al., 2010). Elevated lev-
els of TxA2 in CSF have been reported in patients after SAH and
ICH (Pickard et al., 1994; van Kooten et al., 1999b). TxA2 mediated
activation of TP receptors expressed on platelets surrounding the
region of the brain (cortex and striatum) has been linked to exac-
erbating ICH injury (Kong et al., 1991; van Kooten et al., 1999a;
Saloheimo et al., 2005; Yalcin et al., 2005). Due to the expres-
sion and distribution of TP receptor in the brain, TP receptors
could be considered an ideal therapeutic target for the treatment
of ICH. Platelet activation is often a reflection of vascular risk
factors, diffused atherosclerotic lesions, or the extent of damage
caused by stroke. Terutroban, a selective TP receptor antagonist
(K i= 0.82 nM) used as an antithrombotic agent, could also be
used to prevent atherothrombosis and ischemic stroke (Chamorro,
2009). Using a spontaneous hypertensive stroke-prone rat model,
terutroban increased the survival rate by reducing systemic inflam-
mation, thus promoting the TP receptor antagonists therapeutic
intervention for stroke as a possible antithrombotic agent in
human compared to aspirin alone (Gelosa et al.,2010). However, in
a recent human study, no significant differences in outcomes were
recorded between terutroban and aspirin in patients with cerebral
ischemia (Bousser et al., 2011). Several receptors are upregulated
following ischemia and the mulifactorial nature of ischemia may
explain the lack of effect of many substances tested in clinical tri-
als. These accumulating data warrant further examination of the
therapeutic potential of TP receptors and their selective ligands to
fully elucidate their role in ICH.
PGD2-DP2 (OR CRTH2) RECEPTOR
One of two PGD2 receptors, DP2 receptor, is the most recently dis-
covered. DP2 receptor was initially cloned as an orphan receptor
and later identified as T helper cell type 2 cells (Th2), specific sur-
face PGD2 receptor (Nagata et al., 1999a,b; Hirai et al., 2001). The
DP2 receptor is distinguished by their similarity to chemoattrac-
tant receptors and thus, they are also known as chemoattractant
receptor-homologous molecules expressed on Th2 cells (CRTH2;
Monneret et al., 2001). The CRTH2 receptors are also known as
DP2 receptor based on their similar binding affinity to that of
DP1 toward PGD2, although the DP1 and DP2 receptors do not
share structural homology (Hirai et al., 2001). Similar to many
chemoattractant receptors, the DP2 receptor is coupled to Gαi-
proteins, leading to the inhibition of cAMP and increase in Ca2+
in a variety of cell types (Sawyer et al., 2002). Given the role of the
DP2 receptor in inflammatory diseases such as asthma, blocking
of DP2 receptor represents a novel therapeutic approach for the
treatment of such conditions.
Despite its expression in the spinal cord and its anti-
inflammatory effect as an activator of peroxisome proliferator-
activated receptors, little is known about the role of DP2 receptors
after stroke (Genovese et al., 2008; Grill et al., 2008; Morgenweck
et al., 2010). Based on the role of the DP2 receptor in cAMP inhi-
bition and Ca2+ activation, we hypothesize that activation of this
receptor could lead to aggravated brain damage and its inhibition
could lead to better functional and anatomical outcomes after ICH.
Moreover, blockade of this receptor could result in more availabil-
ity of PGD2 to DP1 receptor, which could then lead to increased
cAMP level and subsequent neuroprotection as we have previously
reported (Saleem et al., 2007c; Ahmad et al., 2010a). We hypoth-
esize that blockade of DP2 receptor following ICH will result in
greater injury based on the increased injury we observed with
DP1−/−mice following ischemic stroke and acute NMDA-induced
excitotoxicity due to similar binding affinity to DP1 receptor, DP2
receptors would have little therapeutic potential in ICH (Ahmad
et al., 2010a).
CONCLUSION
Intracerebral hemorrhage accounts for 13% of all strokes in
the United States each year. Following ICH, extravasated blood
accumulates and compresses the surrounding brain tissue and
treatment is primarily supportive with poor clinical outcome.
To improve the outcome of ICH patients, a better understand-
ing of the pathogenesis of ICH-induced brain injury is needed.
We and others have identified prostaglandin receptors as poten-
tial therapeutic agents against ischemic stroke. Prostaglandins and
their receptors regulate many physiological, inflammatory, and
immunological processes. In the CNS, the role of prostaglandin
receptors has been essentially first elucidated by gene-deletion
studies and evidence suggests these receptors are a therapeutic
target for the treatment of stroke. However, the therapeutic poten-
tial of prostaglandin receptors in ICH remains to be elucidated.
Understanding the integration of a network of prostaglandin
receptor signaling would improve our knowledge of these puta-
tive therapeutic targets for the effective treatment of neurological
diseases. Evidence supports that prostaglandin receptors play a
cooperative and/or sequential role in ICH-mediated inflamma-
tion and neurotoxicity. Intracellular signaling pathways activated
by prostaglandin receptors in ICH are likely to be different than in
ischemic stroke. However, we hypothesize that evolutionary regu-
lated prostaglandin receptor signaling will be conserved and there-
fore this group of receptors, found to have a given role in ischemia
may also have a unique role in hemorrhagic stroke. However it
remains to be determined whether the effect of these receptors
will be similar. Also, identification of a multitude of intracellu-
lar protein interactions with prostaglandin receptors may prove
to regulate their neuronal expression, selectivity toward ligands,
and crosstalk with cytokines, chemokines, and neurotransmitters.
Studying these interactions and the cell-specific functions will help
map a detailed network of signaling that would be necessary for an
injury-induced cellular response. The discovery of a prostaglandin
receptor specific intracellular response may enable us to navigate
a complex pathway leading to the discovery of beneficial drugs for
the treatment of hemorrhagic stroke.
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